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1. Introduction
The liquid biopsy has emerged as a diag-
nostic and prognostic tool in cancer, over-
coming many of the drawbacks associated 
with conventional tissue-biopsy based 
methods. Several biomarkers in the blood, 
such as circulating tumor cells (CTCs) 
and cell-free nucleic acids (cfNAs), are 
finding use in the laboratory and in the 
clinic to guide important clinical decisions 
regarding cancer diagnosis and therapies. 
These circulating markers also give us a 
window to study cancer biology, including 
dissemination and metastasis, and may 
eventually assist in the clinical setting by 
identifying patient’s potential for metas-
tasis after surgery for early stages of cancer.
Exosomes, secreted by various cells and 
released into extracellular environments, 
are nanometer-sized vesicles conformed 
by a phospholipid bilayer. Recent studies 
showed that exosomes contain a number 
of proteins and nucleic acids allowing 
them to function as vesicular messengers 
between cells. Cell to cell communica-
tion was previously thought to be pos-
sible only by several well-known signaling 
methods including endocrine, paracrine, 
and juxtacrine (contact-dependent) signaling. The role of exo-
some-mediated intercellular communication is quickly gaining 
interest. Studies have highlighted that exosome mediated cell-
cell communication may play a critical role in disease progres-
sion by facilitating the cell involvement in this process.[1–3] 
Similarly, research reveals that tumor cell-derived exosome or 
tumor microenvironment-derived exosome can spread into 
extracellular environments and promote cancer progression 
and metastasis.[4–6] Therefore, it is both relevant and neces-
sary to further study how these cancer-associated exosome 
could contribute to the diagnostic potential provided by the 
liquid biopsy tool. In order to use these exosomes as diagnostic 
markers, highly purified cancer-associated exosome isolation, 
characterization and validation methods are essential.[7]
Ultracentrifugation (UC) has thus far been the gold 
standard for the isolation of these cancer-associated exosomes 
for biological research. However, this method suffers from 
Extracellular vesicles (EVs) are emerging as a potential diagnostic test 
for cancer. Owing to the recent advances in microfluidics, on-chip EV 
isolation is showing promise with respect to improved recovery rates, 
smaller necessary sample volumes, and shorter processing times than 
ultracentrifugation. Immunoaffinity-based microfluidic EV isolation 
using anti-CD63 is widely used; however, anti-CD63 is not specific to 
cancer-EVs, and some cancers secrete EVs with low expression of CD63. 
Alternatively, phosphatidylserine (PS), usually expressed in the inner leaflet 
of the lipid bilayer of the cells, is shown to be expressed on the outer 
surface of cancer-associated EVs. A new exosome isolation microfluidic  
device (newExoChip), conjugated with a PS-specific protein, to isolate cancer-
associated exosomes from plasma, is presented. The device achieves 90% 
capture efficiency for cancer cell exosomes compared to 38% for healthy 
exosomes and isolates 35% more A549-derived exosomes than an anti-
CD63-conjugated device. Immobilized exosomes are then easily released 
using Ca2+ chelation. The recovered exosomes from clinical samples are 
characterized by electron microscopy and western-blot analysis, revealing 
exosomal shapes and exosomal protein expressions. The newExoChip 
facilitates the isolation of a specific subset of exosomes, allowing the 
exploration of the undiscovered roles of exosomes in cancer progression 
and metastasis.
Small 2019, 15, 1903600
1903600 (2 of 14)
www.advancedsciencenews.com
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.small-journal.com
drawbacks such as lengthy processing time, low recovery 
rates and an inability to handle small sample volumes[8]; these 
drawbacks are offset by ease of use and minimal need for tech-
nical expertise. Several groups have reported on the potential 
and clinical significance of these exosomes.[9,10] For example, 
Marta et al. used ultracentrifugation to isolate exosomes from 
ovarian cancer patients and showed that plasma from ovarian 
cancer patients contained higher levels of exosomal proteins 
compared to those from benign tumor patients or healthy 
controls.[9] Recently, An et al isolated exosomes from pancre-
atic cancer patients and were able to demonstrate the role of 
these exosomes in inducing cell migration in ex-vivo experi-
ments, supporting the idea that exosomes may be involved 
in metastasis.[10] However, UC-based isolation methods are 
unable to distinguish exosomes from other extracellular 
vesicles or large protein debris having similar density. Addi-
tionally, the need for many washing and handling steps during 
UC inevitably cause a high degree of sample loss, which is a 
distinct disadvantage for samples with a low starting number 
of exosomes. Recently, polymer-based exosome isolation kits 
have been developed and are available in the market. These kits 
use comparably low-speed centrifugation for exosome isolation 
with the help of polymer-assisted nanoparticle precipitation in 
liquid phase. Although their inclusive sedimentation of vesicles 
is helpful for downstream analysis, there is loss of specificity, 
which makes quantitative analysis of exosomes difficult.
Microfluidics technologies offer many advantages and may 
become the optimal method for exosome isolation in the future. 
Owing to recent advances in microfluidic technologies, several 
microfluidic devices for exosome isolation have been developed 
with better recovery and shorter processing times compared to 
UC.[11–17] Among them, immunoaffinity-based microfluidic isola-
tion using antibodies against exosomal surface proteins is advan-
tageous as it allows for high specificity exosome isolation from 
heterogeneous samples, such as plasma, serum, or urine. This 
method also has been incorporated with an engineered surface 
or characteristic patterns in order to enhance the efficiency of 
exosome isolation.[11,12,14] As an example, antibodies against the 
tetraspanin CD63 have been widely applied to exosome isolation 
from the plasma of patients with ovarian cancer, breast cancer, 
and glioblastoma.[12,14,18–21] However, anti-CD63 is not a specific 
biomarker for any one cancer, and its expression is known to vary 
depending on the type of cancer.[22] Recent studies using clinical 
samples showed that only 69.56% of lung cancer patients have 
CD63 positive exosomes with comparably low absolute expres-
sion level compared to other exosomal markers.[23,24] To date, a 
few cancer specific exosomal proteins such as epidermal growth 
factor receptor (EGFR), prostate-specific antigen (PSA), and epi-
dermal growth factor receptor 2 (HER2) have been incorporated 
into microfluidics for cancer-associated exosome isolation for 
lung, prostate, and breast cancers, respectively.[25–27]
In addition to targeting exosomal surface proteins, alterna-
tive approaches to target certain types of exosomal lipids have 
been studied by a few groups. Mass spectrometry has revealed 
a two- to threefold greater enrichment of cholesterol, sphin-
gomyelin, glycosphingolipids, and phosphatidylserine (PS) in 
exosomes compared to cells.[28]
Among the lipids, PS is a type of phospholipid that lies 
within the inner leaflet of the normal cell membrane but 
becomes externalized in malignant and apoptotic cells. Because 
exposed PS typically functions as an ‘eat me’ signal for macro-
phages in our immune system, these cells or vesicles with PS 
are generally removed from circulation. Recent studies have 
revealed that PS is externalized not only on apoptotic cells but 
also on microvesicles and exosomes during vesiculation.[29–32] 
A few studies have also reported that PS expression on the 
membrane leaflet is more abundant in cancer cells[33] and 
cancer cell derived exosomes[34] compared to those from healthy 
controls. In order to detect and quantify the PS expression 
on cells or vesicle surfaces, several proteins have been tested 
and specific binding affinities of Tim4[35] and annexin V[36] to PS 
have been proved. One of the most widely studied PS-binding 
molecules, annexin V, is a 35.8 kDa protein which binds PS in 
a calcium-dependent manner.[37] Given that PS expression on 
cancer cells and cancer cell-derived exosomes is higher than 
those of normal cell and normal cell-derived exosomes, one 
can posit that cancer-derived exosomes can be isolated using 
an annexin V-immobilized microfluidic device, and the isolated 
specific exosome can be released by Ca2+ chelation. Moreover, 
this lipid-based isolation is more likely to enrich the purified 
exosomes regardless of their CD63 expression, making it fea-
sible to isolate the cancer exosomes from CD63-downregulated 
cancers, such as lung cancer. Recently, there have been attempts 
to isolate cancer derived exosomes using their characteristic 
lipid expression.[35,38] Wataru et al. used T-cell immunoglob-
ulin mucin protein 4 (Tim-4) to isolate extracellular vesicles. 
They immobilized Tim4 on conventional magnetic beads and 
applied them to cell culture supernatant with hematopoietic 
and cancer cells. Their results from extensive downstream anal-
ysis of isolated exosomes showed PS-based extracellular vesicle 
isolation is feasible. They did not, however, demonstrate the 
feasibility of the release of these extracellular vesicles from a 
microfluidic device for further downstream applications. Sim-
ilar to Wataru’s work, Huiying et al. used Tim4 beads to purify 
extracellular vesicles before the quantitative detection of CD63-
positive exosomes. Using 10 serum samples from patients with 
hepatocellular cancer, they showed that PS-based purification 
of exosomes allowed for the distinguishing of cancer patients 
from healthy donors.[38] However, they still used CD63 for 
exosome confirmation, therefore this platform may not be 
applicable to patients whose cancers present downregulated 
CD63. To the best of our knowledge, there are no known 
studies that report on lipid-affinity-based microfluidic exosome 
isolation and their clinical applications.
Our group previously presented the ExoChip which iso-
lates exosomes using microfluidic devices using anti-CD63-
exosome affinity.[11] Its novel design and significance revealed 
that exosomes can be efficiently isolated from the serum sam-
ples, and that their downstream analysis might give us clues 
regarding their role in cancer biology. However, due to the lack 
of releasing mechanism of the captured exosomes, qualitative 
analysis and functional studies of exosomes have been limited. 
Taking into consideration the greater merits of lipid-affinity-
based exosome isolation, we present a newer version of our 
exosome isolation microfluidic device, newExoChip. The annexin 
V immobilized microfluidic is designed with alternating narrow 
and wide ripple-like design inspired by the ExoChip that 
enhances the binding interaction between specific exosomes 
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and PS-targeting molecules, thus resulting in higher capture 
efficiency and purity at conditions of high flow rates (Figure 1). 
Compared to our previous ExoChip, the newExoChip having 
225 times more micro-sized circular chambers, enabling faster 
sample processing with higher selectivity (Table S1, Supporting 
Information). We extended our study to clinical blood samples 
from patients with non-small cell lung cancer (NSCLC) and mel-
anoma in order to verify the translational potential of our devices. 
Liquid biopsy studies in lung cancer have mostly been limited to 
CTCs and circulating tumor DNA (ctDNA), many of which still 
require clinical validation as diagnostic and prognostic markers. 
More recently these studies have included cancer exosomes, 
where groups have described important correlations between 
tumor progression and exosome numbers. Patients with lung 
adenocarcinoma presented with higher numbers of exosomes in 
the blood compared with healthy controls.[39] Accumulating evi-
dence suggests that exosomal cargos in lung cancer serves as a 
potential biomarker for diagnosis and prognosis. However, due 
to limitations pertaining to sensitivity of the technologies, com-
prehensive studies are lacking. Similarly, in another aggressive 
cancer, malignant melanoma, there have been few studies that 
have reported that conventional exosome isolation methods may 
not be useful in distinguishing cancer from healthy controls due 
to limited number of melanoma-associated exosomes that are 
shed into the blood.[40] Therefore, we have focused our efforts in 
studying our new device in these two cancers.
2. Results and Discussion
2.1. Evaluation of Binding Affinity between newExoChip Device 
and Cancer Exosomes
For the initial performance evaluation of the microfluidic exo-
some isolation, we used two quantitative analysis methods: 
1) 3,3′-dioctadecyloxacarbocyanine perchlorate (DiO) lipophilic 
dye staining and 2) Scanning electron microscope (SEM). The 
DiO staining, which is specific to the lipid bilayer that encom-
passes extracellular vesicles, is beneficial for simple confirma-
tion of exosome isolation using conventional fluorescence 
microscopy. DiO staining showed greater fluorescence intensity 
on the newExoChip compared to devices that had not been func-
tionalized and devices with no antibody (Figure 2). These results 
demonstrate that the present device is capable of capturing vesi-
cles via specific interaction through annexin V and not by non-
specific binding. From preliminary studies using small chamber 
devices and polydimethylsiloxane (PDMS) blocks (Supporting 
Information S5), we confirmed that annexin V captured more 
Small 2019, 15, 1903600
Figure 1. newExoChip design and working principle. a) The fabricated newExoChip features 30 × 60 circular patterns with a diameter of 500 µm in 
standard slide glass size. b) The mechanism of the capture and release of cancer-associated exosomes using Ca2+-dependent binding between PS and 
annexin V and ethylenediaminetetraacetic acid (EDTA)-based Ca2+ chelation, respectively.
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exosomes compared to an anti-CD63-based immunoaffinity 
method. As such, we have demonstrated that when used with 
microfluidics, annexin V-conjugated devices are able to capture 
and release high numbers of exosome-like vesicles.
The SEM analysis gave us more detailed capture quantifica-
tion and size information about the exosomes captured on our 
device. SEM results verified successful isolation, and the sub-
sequent release, of particles using the newExoChip functional-
ized with annexin V. A control sample was run using a device 
without annexin V conjugation and shows negligible non-
specific binding of exosomes. Microscope images of the devices 
after release showed a lower concentration of exosomal parti-
cles attached to the device as compared to the samples where 
no release was performed. From SEM images, the sizes of cap-
tured exosomes are in the range of exosome sizes reported by 
previous studies.[41–43] These data verified that the newExoChip, 
when functionalized with annexin V, is capable of both selec-
tively capturing exosomes where a non-functionalized device 
could not and releasing a considerable number of exosomes 
after calcium chelation using EDTA.
2.2. Optimization of the newExoChip Devices and Sample 
Processing Conditions
The device has been optimized with respect to optimal concen-
tration of reagents, sample volume, and processing flow rates. 
This optimization was evaluated in terms of capture efficiency, 
release efficiency, specificity, and recovery rate. The defini-
tions of those terminologies are summarized in Supporting 
Information S6. In brief, capture efficiency is the fraction of 
the isolated exosome-sized vesicles by the device compared to 
initial number of spiked exosome in the initial sample. Release 
efficiency is the fraction of the released exosomes from the 
device using calcium chelating agent compared to the number 
of the isolated exosomes. Specificity is the fraction of exosome-
sized vesicles compared to the whole concentration of vesicles. 
Recovery rate is another term for more heterogeneous sam-
ples, such as plasma and cell culture supernatant. This term 
is defined as the fraction of exosomes released from the device 
compared to sum of exosome-sized vesicles in capture effluent 
and release resultant. For calculating the aforementioned 
evaluation criteria in quantitative way, we used Nanoparticle 
Tracking Analysis (NTA) on Malvern’s NanoSight and evaluated 
size distribution and exosomal concentration of samples.
First, the annexin V concentration for device conjuga-
tion was optimized. Three different amounts of biotinylated 
annexin V were evaluated in terms of spiked exosome cap-
turing efficiency. NTA analysis shows higher capture efficiency 
of A549 derived exosomes when the device was conjugated with 
over 600 ng (10 µL) of biotinylated annexin V as opposed to 
the device with 300 ng (5 µL) (Figure 3a). Even though 900 ng 
(15 µL) showed slightly higher capture efficiency of A549 
Small 2019, 15, 1903600
Figure 2. DiO staining and SEM microscopy analysis for confirmation of exosome capture and release using DiO-stained A549-derived cancer exosome 
sample. a) A fluorescent image of a circular pattern (scale bar = 100 µm) (top) and an SEM image of the surface on pattern (bottom) after isolation, 
b) after release, and c) control device after capture. All devices use the same mount of A549 exosomes.
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exosomes, the difference between 600 and 900 ng was insignifi-
cant. As such, we immobilized the biotinylated-annexin V with 
a dilution ratio of 1:10 (600 ng) for all subsequent experiments. 
In order to determine the optimal concentration of EDTA for 
Ca2+ chelation and subsequent exosome release, four different 
EDTA concentrations were applied to the device after capture. 
Theoretically, using the same molar concentration of EDTA in 
the release solution to that of Ca2+ in the binding buffer solu-
tion (2.5 mm) is enough for full chelation of calcium between 
the device surface and exosomes. However, we found that a 
higher EDTA concentration, up to 20 mm, worked well in our 
system. Release efficiency rose steadily with increasing EDTA 
concentration, reaching peak efficiency at 20 mm and drop-
ping at 40 mm (Figure 3b). Therefore, 20 mm was decided as 
Small 2019, 15, 1903600
Figure 3. Device optimization using A549-derived exosome samples. a) Amount of biotinylated annexin V for functionalization. b) Concentration of 
EDTA solution to release. c–f) Finding optimal flow rate for sample processing in terms of c) capture efficiency, d) release efficiency, e) specificity of 
released sample, and f) recovery rate.
1903600 (6 of 14)
www.advancedsciencenews.com
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.small-journal.com
the optimal concentration. Recent studies showed that high 
concentrations of EDTA solution may affect vesicle fusion or 
aggregation by promoting fluidization and destabilization of 
membranes.[44,45] Our NTA size distribution results were also 
in accordance with these results, showing aggregated particles 
sizing over 200 µm at high EDTA concentrations (Figure S6, 
Supporting Information).
To evaluate the optimal flow rate of the device, we used four 
different sample flow rates and collected the initial sample 
before processing, the effluent after exosome capture, and the 
sample after release. The quantity of exosomes captured and 
released have been calculated based on the concentration dif-
ferences between the initial sample and the sample following 
release. From the experiments with the PDMS block and small 
chambers, we did not see any difference in release concentra-
tion with change in flow rate. As a result, we fixed the release 
condition as 1 mL h−1, which is significantly higher than that 
for exosome capture. Figure 3c,d demonstrates that a capture 
flow rate of 900 µL h−1 offered the highest capture efficiency 
on average, but average release efficiency seemed to decrease 
for samples ran at this rate compared to two slower flow rates. 
At 1200 µL h−1, there was a decrease in capture efficiency with 
an additionally lowered release efficiency. This could imply 
that high flow rates lead to exosome capture that caused the 
device to become too congested for effective flow of EDTA 
and the subsequent vesicle release. However, 1200 µL h−1 did 
offer the highest specificity (Figure 3e), meaning a higher 
concentration of particles outside of the typical size range for 
exosomes collected at the outlet during sample processing. 
Both 300 and 600 µL h−1 offered a relatively even distribution 
of capture efficiency, release efficiency, and specificity. Because 
600 µL h−1 offered higher capture and release efficiencies with 
minimal decrease in specificity (Figure 3f), it was deemed 
optimal for this study and applied to the newExoChip.
2.3. Comparison with Tetraspanin-Based ExoChip Devices
As the majority of immunoaffinity-based exosome isolation 
methods use tetraspanin proteins as a target to capture, we 
compared our results with ExoChip devices conjugated with 
antibodies against the tetraspanin proteins CD63, CD9, and 
CD81 in terms of cancer-associated exosome capture and recov-
ering performances (Figure 4).
First, using DiO staining we aimed to compare the exo-
some capture performance between the newExoChip and the 
other immunoaffinity methods. Additionally, two devices, 
one with and one without avidin functionalization, were used 
as control devices after blocking. We used the same quantity 
of A549 exosome spiked in PBS as an initial sample and fol-
lowed by DiO staining and additional washing. The staining 
showed considerably higher fluorescence intensities and bound 
particles on the device with annexin V mediated isolation com-
pared to the other devices (Figure 4a). Again, the entire region 
of the device after DiO staining was scanned and we evaluated 
the relative fluorescence expression for each device (Figure 4b). 
The relative fluorescence intensity from the newExoChip is con-
siderably higher than other devices and the intensities from 
other tetraspanin-based devices were similar to that of the 
avidin functionalized control ExoChip. In order to evaluate 
this result more quantitatively, we evaluated the capture perfor-
mance of each device by comparison between initial exosome 
number and the resultant number after a capturing event. This 
quantitative comparison also yields significantly higher cap-
ture efficiencies on average for those devices functionalized 
with annexin V. The average capture efficiency for annexin V 
functionalized devices was found to be around 90% (Figure 4c), 
whereas the highest, average capture efficiency associated with 
an anti-tetraspanin device was found to be just over 40% for 
device conjugated with anti-CD63. Based on these results, 
the expression of PS on the surface of exosomal membranes 
is more reliable than the expression of these commonly used 
tetraspanins for A549 lung cancer cell derived exosome.
Next, we extended our study with three conditions, annexin 
V, anti-CD63 and a control device with avidin functionalization, 
and evaluated the quantity of exosomes captured and released 
using NTA (Figure 4d,e). After processing, exosomal concentra-
tion in the effluent collected from the outlet of the newExoChip 
was lowest in devices treated with annexin V, followed by those 
captured with anti-CD63, and greatest in the control devices 
that did not undergo any kind of surface modification. In other 
words, the control devices yielded the lowest capture efficien-
cies as expected given that the only means of capture is non-
specific binding of particles within the devices.
Exosomal concentrations of collected samples follow the 
opposite trend, with annexin V devices yielding the highest 
mean concentration after EDTA release and anti-CD63 yielding 
a mean concentration marginally higher than that of the con-
trol devices. It follows that the annexin V recovery rate is 
notably higher than those of anti-CD63 and without antibodies. 
One would expect the concentration of exosomes in the device 
effluent after release for a device with antibody to be greater 
than the concentration after processing, as shown with annexin 
V; however, devices treated with anti-CD63 exhibit the opposite 
trend, speaking to the benefit of using reversible PS-annexin V 
reaction. Annexin V also offers the highest specificity towards 
vesicles in the exosome size-range within a relatively small 
range of values as compared to devices conjugated with anti-
CD63 and those without any capturing molecules. These NTA 
results support previous DiO staining results.
2.4. Device Performance Verification Using Model Samples 
with Healthy and Cancer Cell Line-Derived Exosomes
After device optimization, we prepared several different 
exosome samples from different sources and evaluated the cap-
turing ability of our device. These include exosomes from two 
lung cancer cell lines (A549 and H1975), two melanoma cell 
lines (SK103 and SK19) and a normal lung fibroblast cell line 
(MRC-5). Cell line derived exosomes were processed through 
the device after initial purification using ultracentrifugation and 
the exosomes were spiked into buffer solution at the 
concentration of 1 × 108 exosomes per mL for verification. 
All cancer cell-derived exosomes consistently yielded high 
capture efficiencies using the newExoChip with an average cap-
ture efficiency of 90.19 ± 5.70%. However, normal cell derived 
exosome showed a significantly lower capture efficiency of 
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38.43 ± 15.80%. This could suggest that cancer cell derived 
exosome samples express more PS on their surfaces and 
therefore have a higher probability of binding to the annexin 
V compared to that of normal cell derived one. We also evalu-
ated the recovery rate and specificity of the cell line exosomes, 
and they showed similar trends to the capture efficiency, with 
a lower recovery rate for MRC-5 exosomes than any others 
(Figure 5a). Even though MRC-5 exosomal quantity after release 
was significantly lower than others, its purity was high. Interest-
ingly, even though capture efficiency of H1975 was very high, its 
recovery rate was slightly lower than other cancer exosome cases, 
implying that release performance might vary depending on the 
source of the exosomes. After release, the size distribution of the 
released exosomes was carefully evaluated to see the differences 
Small 2019, 15, 1903600
Figure 4. The comparison of the exosome recovery between Annexin-V based newExoChip and anti-tetraspanin-based ExoChip. a) A549 exosome 
isolation performance comparison based on DiO staining (scale bar = 200 µm). b) Fluorescence intensity of each device after DiO staining. c) A549 
capture efficiencies based on nanoparticle tracking analysis (NTA). d,e) A549 exosome isolation performance comparison based on nanoparticle 
tracking analysis.
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between the sources of origin (Figure 5b). It is noteworthy that 
the average size of lung cancer cell derived exosomes was bigger 
than those of melanoma and normal cells. D-values of the lung 
cancer exosomes are also bigger than the others and it could be 
meaningful if further studies and verification are fulfilled.
2.5. Isolation of Exosomes from In-House Lung Cancer Patient 
Circulating Tumor Cell Line Supernatant and Healthy Donor 
Exosome Samples
Before the use of our devices with clinical samples, we pre-
pared exosomes from two in-house lung cancer CTC lines to 
both determine the heterogeneity and the capture efficiencies 
of patient-derived exosomes. These two CTC cell lines origi-
nated from two different lung cancer patients, and their in-vitro 
supernatants without fetal bovine serum (FBS) were used as 
samples for our devices. The device without Av immobilization 
was used as a control device. After release, the release solu-
tion’s exosomal concentration and size profiles were measured 
by NTA. In both cases, our devices isolated significantly higher 
quantities of exosomes than control devices (Figure 6a). How-
ever, the concentration and size profile were varied between 
exosomes derived from the two CTC lines. CTC-R1 derived 
exosomes shows higher concentration but smaller size profile 
compared to CTC-R2, showing the heterogeneity of exosomes 
depending on the sample (Figure 6b). As such, we can expect 
that the exosomal concentration and size will vary from patient 
to patient. In addition to this experiment, we also pre-purified 
an aliquot of CTC-derived exosomes samples using ultracen-
trifugation and used one purified healthy donor (HD) exosome 
sample (System Biosciences) to evaluate the recovery rates 
and purity after release using the newExoChip. We then used 
the same concentration of each of the three different exosome 
samples to account for varying capture rates based on initial 
concentration. We could clearly see that the two CTC-derived 
exosomes show considerably higher recovery rate than the 
HD’s exosomes, which is similar our cancer and normal cell 
line results (Figure 6c). Despite significant differences in exo-
somal concentration and sizes between the two CTC-derived 
Small 2019, 15, 1903600
Figure 5. Cancer cell and normal cell derived exosome recovery using newExoChip. a) Recovery rates and specificities of five different cancer/normal 
cell derived exosome samples. b) Size distribution analysis in terms of mean, mode, and D-values (D10, D50, and D90) after release of exosomes 
using newExoChip.
Figure 6. The in-house lung cancer circulating tumor cells (CTC) line-derived exosome isolation using newExoChip. a) Exosome concentration after 
release using present devices and control devices. b) Size distribution analysis of vesicles recovered by newExoChip. c) Recovery rates and specificities 
of CTC-derived exosomes and comparison to healthy donor plasma exosomes using newExoChip.
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exosomes, their recovery rates are similar and remained high 
enough to be distinguished from HD exosomes.
2.6. Performance Comparison with Conventional Exosome 
Isolation Methods Using Model Samples
Thus far, there are several exosome isolation methods com-
mercially available and ultracentrifugation and polymer (PEG) 
based exosome kits have been widely used by many researchers 
due to the relatively low technical barrier. Therefore, we com-
pared our newExoChip’s performance with these methods using 
multiple model samples. First, we used the model sample 
containing a known quantity of A549-derived exosomes 
spiked (5 × 108 exosomes per mL) in PBS buffer. Using the 
identical concentration and volume of the initial sample, our 
newExoChip captured 67.26% of spiked exosomes while ultra-
centrifugation captured only 5.52% of exosomes (Figure 7a). 
Ultracentrifugation has been widely accepted as a gold standard 
for exosome capture, however, it shows substantial sample 
loss during the multiple processing steps when the amount of 
target exosome is very limited.
Similarly, by using our in-house CTC cell line, CTCR1, 
derived media supernatant after removal of cellular debris, the 
newExoChip yielded exosomal concentration and purity per-
centages of 4.26 × 108 and 47.29%, respectively as compared 
to ultracentrifugation which yielded 2.12 × 108 and 89.6% 
(Figure 7b). Notably, the average purity of the sample after 
ultracentrifugation was higher than that for the newExoChip, 
indicating lower selectivity compared to ultracentrifugation. 
However, as a whole, the recovered number of exosomes is 
still more effective with the newExoChip, which will be more 
effective for determining accurate counts of exosomes within 
patient samples. At the same time, annexin V might capture 
apoptotic bodies expressing PS too, so it might be useful to 
remove bigger debris for clinical studies. The highest exo-
somal concentration was achieved using the PEG-based kit, 
at 1.28 × 109 exosomes with a purity of 72.90%, both notably 
higher than those values for the newExoChip. However, the 
NTA data suggest that this kit is not fully capable of cap-
turing smaller vesicles (30–50 nm) (Figure S7, Supporting 
Information), which may make this method unreliable by 
way of excluding smaller sized exosomes for downstream 
analysis.
Small 2019, 15, 1903600
Figure 7. The exosome isolation performance between newExoChip and conventional exosome isolation methods. a) Comparison by using A549 
exosomes spiked in PBS. b) Comparison by using CTC cell line culture supernatant. c,d) Comparison of the exosome recovery between newExoChip and 
ultracentrifugation using clinical samples. Exosomal concentration after recovery (c) and purity of the recovered samples after isolation (d).
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2.7. Performance Comparison with Ultracentrifugation Method 
Using Plasma Samples
Using four different clinical plasma samples from cancer 
patients and healthy donors, we aimed to compare our exosome 
recovery performance with the gold standard ultracentrifugation 
method. We compared these results in terms of exosome-like 
vesicle recovery and sample purity after recovery (Figure 7c,d). 
In all cases, we used identical volumes of initial plasma 
samples and resuspended them in equal volume of buffer solu-
tion. From this study, other than one healthy donor (HC-D), 
the newExoChip captures significantly more exosomes than UC, 
and this tendency was more significant in two cancer cases 
(Figure 7c). Processing samples with the newExoChip offers 
higher purity than with ultracentrifugation for both healthy 
and cancer samples, as well as a significantly greater concentra-
tion of exosomal particles for cancer samples (Figure 7d). The 
present newExoChip appeared to be more effective when pro-
cessing samples from cancer patients.
2.8. Isolation of Exosomes from Plasma Samples of Cancer 
Patients and Healthy Donors
We extended our study to 12 clinical plasma samples from 
lung (n = 4), melanoma (n = 3) and healthy donors (n = 5). In 
all cases, we used 30–100 µL of plasma samples for exosome 
isolation using our newExoChip. The concentration, size dis-
tribution, shapes, and proteins expression levels of exosomes 
released from the device were evaluated using NTA, SEM, and 
western blot analysis. Figure 8a shows the various exosome con-
centrations for each patient and by cancer type. Although the 
five healthy donors show similar exosomal concentrations, the 
cancer patients showed a wide range of exosome concentrations. 
The Ma showed the highest (2.79 × 109 per mL) and Ld showed 
the lowest concentration (2.89 × 108). Statistical analysis of par-
ticle size confirmed specificity of most samples, both cancerous 
and healthy (Figure 8b). While there is a wide range of particu-
late sizes captured, the mean size of every sample falls below 
150 nm in diameter, and the mode of each sample (excluding 
Ld) falls lower than the corresponding mean. Interestingly, the 
average size of exosomes from lung cancer was bigger than 
those of melanoma and healthy control. Similar size differences 
were shown in our cell line experiments. This could imply that 
lung cancer exosomes isolated by PS-annexin V affinity might 
be larger than usual or that another majority of extracellular ves-
icles in lung cancer might affect this size distribution. However, 
this information, along with the median values, showed that a 
considerable portion of samples collected from all sample types 
fall within the exosomal size range. The varying sizes of cap-
tured exosomes were also verified by SEM analysis (Figure 8c). 
Small 2019, 15, 1903600
Figure 8. Isolation of exosomes from clinical samples from cancer patients and healthy donors. a) Vesicle size distribution regarding mean, mode, and 
D-values (D10, D50, and D90) after release. b) Exosome concentration after newExoChip-based exosome recovery. c) SEM image of isolated exosome 
and the magnified view of the exosome from a melanoma patient. d) A representative western blot analysis of the protein isolated from newExoChip 
and characterized for exosomal markers and intracellular protein marker in five different cancer patients’ plasma samples.
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In order to confirm that the captured vesicles from our device are 
exosomes, we used western blot analysis to verify the expression 
of exosomal markers. Instead of using CD63, which is known 
to have lower expression on lung cancer exosomes, we used 
CD9 and Flotillin-1 as exosomal markers. From the western blot 
analysis using three lung plasma samples and two melanoma 
samples, we see positive bands for both exosomal markers 
(Figure 8d). Additionally, the samples were probed for beta-actin 
as a standard loading control and calnexin to verify that there 
was no cellular contamination within the samples.[46,47]
3. Conclusion
The present study showed that our PS targeting microfluidic 
device is capable of capturing tumor-associated exosomes more 
efficiently than the previous ultracentrifugation method and 
well-known exosomal protein marker method. Recently, one 
study of NSCLC exosomal lipids reported that several specific 
exosomal lipids might be useful markers for distinguishing 
advanced cancers from less advanced and normal.[48] Although 
most previous studies have focused on exosomal proteins, 
monitoring the exosomal lipids for alteration depending on 
the disease status might be more suited for clinical use. Even 
though we showed that our method facilitates effective exo-
some isolation, the exosomes isolated may be one subset of 
exosomes, which means this result and clinical meaning need 
to be interpreted with caution. This PS expression might not be 
specific to cancer only as some immune cell also might express 
PS during their progression. We captured natural killer cell 
line (NK-92MI) derived exosomes and we found that our device 
recovers more than 90% of spiked natural killer (NK) exosomes 
(Supporting Information S8). In addition to PS expression of 
NK exosomes, the PS expression at the exosomal surface seems 
to also be related to the immune response of the body. Keller 
et al. showed that uptake of ovarian carcinoma exosomes by 
natural killer cells require PS on the exosomal surface, implying 
that PS expression is not only resulting feature during vesicula-
tion but also may have certain roles to be regulated by other 
immune cells.[49] Exosomes from tumor cells have been shown 
to have the potential to induce antitumor activity, so their PS 
expression might help its activation.[50] Thus, the exosomes iso-
lated using this PS-based method might be more effective to 
induce immune response, suggesting that this subset might 
be useful for further clinical use. Several prospective studies 
have showed that PS is expressed on cancer derived exosomes 
in ovarian cancer and prostate cancer. In addition to these, our 
studies making use of PS expression on exosomes from lung 
cancer and melanoma is consistent with previous results. These 
results empower the theory that cancer exosomes express PS 
abundantly and may induce some immune response. The pre-
sent newExoChip facilitates the isolation of cancer-associated 
exosomes, thus allowing us to explore the undiscovered roles of 
exosomes in cancer progression and metastasis.
4. Experimental Section
Model Sample Preparation: In order to examine the performance of 
the newExoChip, five different types of model samples were prepared 
depending on the aim of the study. For the evaluation of device 
performance in lung cancer, two different cell line derived exosomes, 
A549 and H1975, were prepared. For A549-derived exosomes, A549-
derived exosomes (SBI) in the concentration of 1 × 1010 per mL (NTA) 
were purchased and diluted into 1× binding buffer solution. For H1975-
derived exosome, H1975 was cultured under the standard cancer cell 
culture conditions using exosome-depleted FBS, and the supernatant 
was ultracentrifuged to isolate the exosomes. After ultracentrifugation, 
the concentration was measured using NTA, and a known number of 
exosomes was used for model sample preparation. In every case for 
newExoChip, annexin V binding buffer 1× was used as a basic buffer. For 
the comparison study with anti-CD63, the same exosome concentration 
was used but was diluted into standard PBS solution. Two patients’ CTC-
derived cell lines were additionally prepared to examine the device’s 
potential for clinical use. Similar to the preparation of cancer cell line-
derived exosomes, those CTC-derived cell lines were cultured with 
in-house media with exosome-depleted FBS for 1–3 days, and their 
supernatants were processed by our devices.
Human Plasma Sample Preparation: The sample collection and 
experiments were approved by University of Michigan Institutional 
Review Board (IRB). Informed consents were obtained from all 
participants of this clinical study and NSCLC and melanoma blood 
samples were obtained after approval of the institutional review board 
at the University of Michigan. All experiments were performed in 
accordance with the approved guidelines and regulations by the ethics 
committee at the University of Michigan. Each blood sample was 
centrifuged at 2000 × g for 15 min to sediment all cells, and then at 
12 000 × g to remove all residual cellular debris. After centrifugation, the 
supernatant was gently collected and stored at −80 °C.
PS-Annexin V Binding Affinity Evaluation: For the initial verification 
of binding affinity between cancer cell-derived exosomes and annexin 
V, the biotinylated-annexin V was immobilized onto small chamber 
devices and square PDMS blocks (Annexin V block) by standard avidin–
biotin conjugation methods. For the negative control, identical device 
and block without annexin V functionalization (blank block) were used. 
The anti-CD63 conjugated PDMS device/block (CD63 block) was used 
as positive control. For the chamber device, static or dynamic sample 
processing was placed. For dynamic sample processing, 200 µL of 
model sample containing DiO-stained A549-derived exosomes was 
gently flowed through the device using a syringe pump at the flow rate of 
0.3 mL h−1 and non-bound exosomes were washed out with the flow rate 
of 0.5 mL h−1. For the release, 20 mm EDTA was flowed through at the 
flow rate of 0.9 mL h−1. For the static sample processing, 50 µL of non-
diluted DiO-A549 stock solution was statically pipetted and incubated 
for more than 12 h in 4 °C. The chamber was washed out by pipetting 
additional binding buffer solution and 20 mm EDTA solution was used 
for the release process. Similar to the static chamber experiments, 
PDMS blocks with/without capturing molecules were exposed to 
DiO-stained A549 exosome stock solution and incubated 1 h for the 
capturing process. For the release, 10–20 mm EDTA solution was used. 
For every step, the devices before/after capture and after release were 
examined under a fluorescence microscope and evaluated by its relative 
fluorescence.
Device Design, Numerical Analysis, and Fabrication: The newExoChip 
device has 30 ripple-shaped channels, and each channel is composed 
of 60 circular channels in a row. Each circle has a diameter of 500 µm 
and the distance between each circle is 900 µm. The junction between 
two adjacent circular patterns has a width of 75 µm. The channels 
that repeatedly expand and shrink were ideally designed for enhancing 
binding affinity between samples and antibody-conjugated patterns. 
The height of the patterns was designed to be 50 µm. It was confirmed 
that these channels increased the binding chance between exosomes 
and annexin V conjugated channels by decreasing flow velocity and 
increasing surface area. These results were found using numerical 
analysis performed in COMSOL (Supporting Information S1). The 
newExoChip is fabricated by standard soft-lithography including mold 
fabrication and PDMS molding (Supporting Information S2). By 
patterning SU8-2050 photoresist on a silicon wafer, the newExoChip mold 
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was prepared and its height of 58.67 ± 2.25 µm was confirmed by alpha-
step measurement. By pouring PDMS and PDMS curing agent mix 
(1:10), PDMS mold was fabricated and the prepared PDMS pattern was 
bonded to clean slide glass by O2 plasma treatment.
Surface Modification: For the surface modification on the device, 
standard avidin–biotin chemistry was used with optimization.[11,17] To 
elaborate, after plasma bonding between PDMS layer and slide glass, 
silane solution (3 mL ethanol + 120 µL silane) was injected three times 
and was incubated 20 min after each injection. The devices were then 
injected and flushed out with ethanol as a washing step. Next, the 
devices were injected with a GMBS mixture (2 mL ethanol + 6 µL GMBS) 
two times and incubated 15 min after each injection. Again, the devices 
were flushed out with ethanol. Following the second washing step, the 
devices were injected with Avidin (1 mL of filtered PBS + 100 µL of 
NeutrAvidin), placed in a Petri dish sealed with parafilm along with wet 
paper napkins, and incubated overnight in a standard refrigerator. After 
1–10 days, the devices were defrosted and washed out with filtered PBS. 
Before the biotinylated annexin V conjugation, the coverage of avidin 
in our device was checked and confirmed using biotinylated staining 
dye (Supporting Information S3). The devices were then injected with 
110 µL of the biotinylated annexin V (10 µL annexin V + 100 µL of 
1× binding buffer): 55 µL into the inlet, a 30-min incubation period, 
55 µL into the outlet, and another 30-min incubation period before use. 
Biotinylated annexin V was incorporated with various avidin-conjugated 
substrates.[51–53]
Devices used for comparison studies with anti-CD63, anti-CD81, and 
anti-CD9 were prepared by standard biotin–avidin antibody conjugation 
methods. The devices were injected with 100 µL of the biotinylated 
antibodies (2 µL biotin antibody solution+98 µL of PBS) the same way 
as with annexin V and washed with PBS. Devices used for controls 
were prepared in two ways: 1) followed by avidin functionalization and 
2) without any functionalization. All control devices were injected with 
3% BSA solution (0.03 g per 1 mL filtered PBS) to prevent nonspecific 
binding and were incubated for at least 30 min before use.
Sample Processing—Exosome Capture and Release: The prepared 
model samples or patient plasma samples were processed using a 
Harvard syringe pump at the flow rate of 0.3–1.2 mL h−1. All samples 
were prepared in the 1× of binding buffer containing 2.5 mm of CaCl2 to 
be actively conjugated with annexin V. 300 µL of sample was withdrawn 
into a 1 mL syringe and connected to the device. After exosome capture, 
200 µL of 1× binding buffer was processed at the flow rate of 1 mL h−1 
to remove the excess unbound vesicles/proteins. For the release of the 
captured exosomes, 300 µL of 20 mm EDTA solution was flowed at the 
flow rate of 1 mL h−1 in two steps; the 1st 150 µL injection and 30 min 
incubation without flow. Another 150 µL was flowed and 200 µL of PBS 
buffer injection was followed at the flow rate of 1 mL h−1 to make sample 
500 µL in total. The samples of 500 µL after capture and release were 
analyzed quantitatively by nanoparticle tracking analysis (NTA).
Field Emission Scanning Electron Microscopy: Immediately following 
capture and release experiments, small portions of each device were 
extracted using a biopsy punch and each punched PDMS specimen was 
fixed in 2.5% glutaraldehyde in PBS for 1 h and then rinsed for 20 min 
with PBS, followed by dehydration with standard ethanol gradients 
solution (50%, 70%, 90%, 95%, and 100%). The specimen was then 
immersed for 10 min in a solution of ethanol/HMDS (1:1) and then 
transferred to 100% HMDS, followed by overnight air drying in the 
hood. The dehydrated specimen was then attached to carbon double 
sided tape, mounted on a SEM stub, and coated with gold by sputtering. 
Devices after capture and release were examined by FEI Nova 200 
Nanolab Dualbeam FIB scanning electron microscope under low beam 
energies (2.0–5.0 kV) at the Electron Microscopy Analysis Lab (MC2) at 
University of Michigan.
DiO Staining of the Extracellular Vesicles: Staining of extracellular 
vesicles using lipophilic dyes such as DiO and PKH has been used in 
various studies.[11,14,15] DiO staining was conducted in two experiments. 
First, the DiO-stained A549-derived exosomes were prepared for the 
model sample experiment. In order to make DiO-stained exosomes, 1 µL 
of DiO staining dye (ThermoFisher, USA) was thoroughly mixed with 
300 µL of stock solution of A549 exosomes. After 20 min of incubation, 
ultracentrifugation was performed to remove excess dye. After another 
ultracentrifugation for exosome purification, the precipitated pellet was 
suspended with PBS and stored in a deep freezer until use (Supporting 
Information S4). For the second experiment, direct DiO staining was 
conducted for quantitative analysis of the exosome capture/release. 
DiO staining was carried out after the normal sample processing and 
washing procedure with no release. 1 µL of dye was added to 200 µL of 
buffer (binding buffer for newExoChip, PBS for controls). Each device was 
injected with 200 µL of the dye solution at a flow rate of 1000 µL h−1 and 
incubated for 20 min without flow. This was followed by a second wash 
at 1000 µ h−1 with buffer solution to remove excess dyes. The binding 
tendency and amount were evaluated under fluorescence microscopy 
LV100 (Nikon, Japan). To compare the quantity of DiO-stained exosomes 
captured on each device, the average fluorescent intensity was calculated 
using Nikon’s NIS Elements software. The average background from 
each device was then subtracted to calculate a standardized average 
fluorescent intensity. The standard deviation was calculated using the 
variation in average intensities across each device.
Ultracentrifugation: Ultracentrifugation was used for two reasons: 
comparison study with newExoChip and DiO-stained extracellular vesicle 
(EV) preparation. EVs were isolated using two different ultracentrifuges, 
Sorvall ultracentrifuge (ThermoFisher, USA) and Airfuge ultracentrifuge 
(Beckman Coulter, USA), depending on the sample volume. For the 
comparison study of model samples, the initial volume was 200 µL and 
the Airfuge ultracentrifugation was used with an A-100/40 angle rotor for 
30 min at 100 000 × g. After the first centrifugation, 170 µL of supernatant 
was removed from the tube and replaced with 170 µL of pre-filtered PBS, 
and then followed by the same centrifugation step. For the comparison 
study of clinical samples, the same volume of initial plasma sample 
was used but diluted into PBS buffer. After the initial ultracentrifugation 
at 100 000 × g for 90 min, the supernatant was aspirated and another 
38 mL of PBS was injected for the 2nd centrifugation at 100 000 × g 
for 90 min. The pellet after the 2nd centrifugation was gently spiked to 
100 µL of PBS and compared to the resultant from newExoChip. For the 
preparation of DiO-stained EV, the same rpm conditions were used but 
an additional centrifugation was performed to remove excess dye debris.
PEG-Based Exosome Isolation Kit: For the comparison study, a 
polymer-based exosome isolation kit, Total Exosome Isolation Reagent 
(ThermoFisher, USA), was used. The isolation of exosomes with the 
kit was done following the user manual of the kit. Briefly, the CTC cell 
line culture media was centrifuged at 2000 × g for 30 min to remove 
cells and debris and 200 µL of the media supernatant was gently mixed 
with 100 µL of the reagent. The mixed sample was incubated at 2 °C 
overnight and after incubation, the sample was centrifuged at 10 000 × g 
for 1 h at 4 °C. Then, the exosome pellet was resuspended with PBS for 
NTA analysis. Each experiment was carried out in triplicate.
Nanoparticle Tracking Analysis: For the evaluation of the concentration 
and the size distribution of the resultant effluent, nanoparticle tracking 
analysis (NTA) was performed using the NanoSight NS300 (Marven 
Instruments, UK). 30 µL of the resultant was used and a laser module was 
mounted inside the main instrument housing. Based on the Brownian 
motion of nanoparticles, this equipment visualizes the scattered lights 
from the particles of interest. This movement was monitored through a 
video sequence for 20 s in triplicate. All data acquisition and processing 
were performed using NanoSight NS300 control software (screen gain, 
7; camera level, 13; detection threshold, 5).
On-chip Protein Extraction and Western Blot Analysis: Exosome lysis 
was performed using RIPA buffer with 1% protease inhibitor. The 
prepared buffer solution was flowed through the device at the flow rate of 
50 µL min−1 right after exosome isolation. Initially, 40 µL of sample was 
injected to remove residual solution in the device and sample collection 
was started after 40 µL. This was immediately followed by an injection of 
50 µL per device at the same rate. Devices were incubated for 5 min, and 
then injected with another 50 µL at 50 µL min−1. Finally, devices were 
manually injected with air to push out as much sample as possible from 
each device. The collected samples were then gently dispersed by vortex 
mixer and kept at −20 °C.
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Total protein was measured by standard BCA analysis according to 
the manufacturer’s instructions. For the released sample, microBCA 
analysis was used because its high concentration in EDTA is not 
compatible to standard BCA analysis. Western Blot analysis was 
performed on a precast 4–20% SDS gel from BioRad. The samples were 
prepared in 4× Laemelli buffer with 2-mercaptoethanol and heated to 
95 °C for 5 min before loading onto the gel. The gel was run at 120 V 
for 1 h before transferring at 120 V for 1 h 15 min on ice. Blocking was 
performed in 5% non-fat milk in TBST for 90 min. Primary antibodies 
were incubated overnight on a rocker at 4 °C at a concentration of 1:500 
(Flotillin-1, Santa Cruz), 1:1000 (CD9, Cell Signaling; Calnexin, Cell 
Signaling), or 1:1500 (Beta-Actin, Cell Signaling) in 3% non-fat milk in 
TBST. Thorough rinsing was performed, and then secondary antibody 
was incubated for 2 h at room temperature (anti-Mouse, Santa Cruz; 
anti-Rabbit HRP, Cell Signaling) at 1:1500 in 3% non-fat milk in TBST.
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